CAC
NVCR icon

Core Alternative Capital’s NovoCure NVCR Stock Holding History

Core Alternative Capital’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-175
Closed -$7.26K – 380
2023
Q2 		$7.26K Buy
+175
New +$10.9K ﹤0.01% 340

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Core Alternative Capital's NVCR Position: Q3 2023 in Review

Core Alternative Capital sold out of NovoCure (NVCR) in Q3 2023, closing a stake of 175 shares — an estimated $7.26K sold.

Core Alternative Capital first reported a position in NVCR in Q2 2023 and held it in 1 quarter. The position peaked at $7.26K in Q2 2023. 226 funds tracked by Wall St. Rank hold NVCR as of Q3 2023.

  • Core Alternative Capital reported no remaining NovoCure position as of Q3 2023 after selling out during the quarter.
  • Core Alternative Capital sold 175 NovoCure shares in Q3 2023, an estimated $7.26K.
  • Core Alternative Capital first reported a position in NovoCure in Q2 2023 and held it in 1 quarter.
  • Core Alternative Capital's NovoCure position peaked at $7.26K in Q2 2023.
  • 226 funds tracked by Wall St. Rank held NovoCure as of Q3 2023.

Based on Core Alternative Capital's 13F filing for Q3 2023, filed 19 Oct 2023.